Core reagent kit sales grew 32% YTD, offsetting declines from discontinued instrument sales, while cost reductions improved gross margin to 78.7%. Net loss narrowed and new product launches and share issues strengthened the company's position.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.